Evolent Health (EVH) Scheduled to Post Earnings on Thursday

Evolent Health (NYSE:EVH) is set to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Evolent Health has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The firm had revenue of $556.06 million for the quarter, compared to analysts’ expectations of $541.87 million. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Evolent Health Price Performance

EVH stock opened at $27.23 on Tuesday. The company has a market cap of $3.14 billion, a PE ratio of -21.44 and a beta of 1.57. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average price of $31.28 and a two-hundred day moving average price of $30.28. Evolent Health has a 12-month low of $23.33 and a 12-month high of $35.83.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EVH. Canaccord Genuity Group decreased their target price on Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, March 28th. Citigroup began coverage on shares of Evolent Health in a research note on Monday, April 22nd. They set a “buy” rating and a $40.00 price objective for the company. Oppenheimer initiated coverage on shares of Evolent Health in a research note on Friday, March 1st. They issued an “outperform” rating and a $45.00 target price on the stock. JPMorgan Chase & Co. reduced their target price on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, March 15th. Finally, William Blair reiterated an “outperform” rating on shares of Evolent Health in a report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Evolent Health has an average rating of “Moderate Buy” and a consensus target price of $42.70.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.